Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer treated with brachytherapy and supplemental external beam

被引：0
|
作者：
Allen, Z.
Merrick, G. S.
Butler, W.
Wallner, K.
Galbreath, R.
Adamovich, E.
Lief, J.
机构：
[1] Wheeling Hosp, Wheeling, WV USA
[2] Puget Sound Healthcare Cooperat, Grp Hlth, Seattle, WA USA
[3] Ohio Univ Eastern, St Clairsville, OH USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15578
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy
    Raldow, Ann C.
    Zhang, Danjie
    Chen, Ming-Hui
    Braccioforte, Michelle H.
    Moran, Brian J.
    D'Amico, Anthony V.
    BRACHYTHERAPY, 2015, 14 (06) : 781 - 787
  • [22] Androgen Deprivation Therapy in High-Risk Prostate Cancer
    Buyyounouski, Mark K.
    ONCOLOGY-NEW YORK, 2010, 24 (09): : 806 - 809
  • [23] Association of Radiation Facility Volume with Overall Survival in Patients with Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy
    Sebastian, N.
    Goyal, S.
    Liu, Y.
    Patel, P. R.
    Hanasoge, S.
    Dhere, V. R.
    Shelton, J. W.
    Godette, K. D.
    Jani, A.
    Hershatter, B.
    Fischer-Valuck, B.
    Patel, S. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E434 - E435
  • [24] Does the Addition of Brachytherapy And/or Androgen Deprivation Therapy to External Beam Radiotherapy Correlate with Improved Survival in Men with Unfavorable Intermediate-risk Prostate Cancer?
    Andruska, Neal
    Agabalogun, Temitope
    Fischer-Valuck, Benjamin
    Brenneman, Randall
    Huang, Yi
    Gay, Hiram
    Michalski, Jeff
    Carmona, Ruben
    Baumann, Brian
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (10): : S59 - S60
  • [25] Predictors of the Use of Supplemental Androgen Suppression Therapy (AST) and External Beam Radiation Therapy (EBRT) in Men with High-risk Prostate Cancer (PC) Undergoing Brachytherapy
    Hattangadi, J. A.
    Chen, M.
    Braccioforte, M. H.
    Moran, B. J.
    D'Amico, A. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S577 - S578
  • [26] Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy
    Beltran, Himisha
    Wyatt, Alexander W.
    Chedgy, Edmund C.
    Donoghue, Adam
    Annala, Matti
    Warner, Evan W.
    Beja, Kevin
    Sigouros, Michael
    Mo, Fan
    Fazli, Ladan
    Collins, Colin C.
    Eastham, James
    Morris, Michael
    Taplin, Mary-Ellen
    Sboner, Andrea
    Halabi, Susan
    Gleave, Martin E.
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6802 - 6811
  • [27] Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy
    Qu, Feng
    Gu, Yue
    Xue, Mengxia
    He, Mingzhe
    Zhou, Fang
    Wang, Guangji
    Peng, Ying
    PROSTATE, 2021, 81 (09): : 560 - 571
  • [28] Quality of life in intermediate or high risk prostate cancer patients treated by external beam radiotherapy and brachytherapy with or without androgen deprivation
    Lacorte-Pi, T. M.
    Guix-Melcior, B.
    Guedea-Edo, F.
    PSYCHO-ONCOLOGY, 2006, 15 (02) : S296 - S297
  • [29] Early biochemical predictors of survival in intermediate and high-risk prostate cancer treated with radiation and androgen deprivation therapy
    Patel, Mira A.
    Kollmeier, Marisa
    McBride, Sean
    Gorovets, Daniel
    Varghese, Melissa
    Chan, Luanna
    Knezevic, Andrea
    Zhang, Zhigang
    Zelefsky, Michael J.
    RADIOTHERAPY AND ONCOLOGY, 2019, 140 : 34 - 40
  • [30] Androgen Deprivation Therapy: A Survival Benefit or Detriment in Men With High-Risk Prostate Cancer?
    Fang, L. Christine
    Merrick, Gregory S.
    Wallner, Kent E.
    ONCOLOGY-NEW YORK, 2010, 24 (09): : 790 - 797
12345